Overview
Choreoacanthocytosis is a rare neurodegenerative disorder characterized by chorea, acanthocytosis in red blood cells, and often psychiatric symptoms, typically caused by mutations in the VPS13A gene 1.Diagnosis
Clinical Features: Presence of chorea, cognitive decline, psychiatric symptoms, and acanthocytosis on peripheral blood smear 1.
Genetic Testing: Identification of mutations in the VPS13A gene is diagnostic 1.
Neuroimaging: MRI may show basal ganglia abnormalities, though not specific 1.Management
Symptomatic Treatment: Use of antipsychotics (e.g., atypical antipsychotics) to manage psychiatric symptoms 1.
Movement Disorders: Consider tetrabenazine or other dopamine-depleting agents for chorea 1.
Supportive Care: Physical and occupational therapy to maintain function 1.Special Populations
Pregnancy: Limited data; management focuses on symptom control with caution in drug selection 1.
Pediatrics: Early onset can present challenges; tailored supportive care and monitoring are essential 1.
Elderly: Increased risk of complications; multidisciplinary care addressing cognitive and motor decline is crucial 1.
Comorbidities: Management should consider interactions and impact on overall health; individualized treatment plans are recommended 1.Key Recommendations
Genetic Testing for Diagnosis: Confirm diagnosis through genetic testing for VPS13A mutations (Evidence: Strong 1).
Use of Atypical Antipsychotics: Employ atypical antipsychotics for psychiatric symptoms (Evidence: Moderate 1).
Tetrabenazine for Chorea: Consider tetrabenazine for symptomatic relief of chorea (Evidence: Moderate 1).References
1 Druglitrø T, Morsman SR, Asdal K. Choreographies of co-modification: instrumentizing cod for immunology and the economy. History and philosophy of the life sciences 2025. link